

Extracellular Cyclic AMP/Adenosine Signaling Pathway: A Potential Pharmacological Target for Therapeutic Intervention in Chronic Lymphocytic Leukemia

Francisco Sandro Menezes-Rodrigues, Paolo Ruggero Errante, Afonso Caricati-Neto and Leandro Bueno Bergantin*

Department of Pharmacology, Federal University of São Paulo, Paulista School of Medicine, Laboratory of Autonomic and Cardiovascular Pharmacology, São Paulo, Brazil

***Corresponding author:** Leandro Bueno Bergantin, Department of Pharmacology-Federal University of São Paulo-Paulista School of Medicine, Laboratory of Autonomic and Cardiovascular Pharmacology, Rua Pedro de Toledo, 669-Vila Clementino, São Paulo-SP, Brazil, CEP: 04039-032, Tel: +55 11 5576-4973; E-mail: leanbio39@yahoo.com.br

Received date: April 05, 2017; **Accepted date:** April 08, 2017; **Published date:** April 10, 2017

Copyright: © 2017 Rodrigues FSM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia in adults of western countries with an estimated annual 15,000 new cases and 4,500 deaths in the USA [1,2]. CLL is a disorder characterized by a progressive accumulation of biologically and functionally incompetent lymphocytes. Clinically, CLL is a heterogeneous disease with variable prognosis depending on the age being dependent on the presence of associated comorbidities, clinical stage and expression of molecular markers to the disease [3-6].

10. Resta R, Yamashita Y, Lippman ME, LF (1998) Ecto-enzyme and signaling functions of lymphocyte CD73. *Immunol Rev* 161:95-109
11. Haskó G, Cronstein BN (2004) Adenosine: an endogenous regulator of innate immunity. *Trends Immunol* 25: 33-39
12. Sitkovsky MV, Ohta A (2005) 'danger' sensors that STOP the immune response: the A2 adenosine receptors? *Trends Immunol* 26:299-304
13. Karin M (1994) Signal transduction from the cell surface to the nucleus through the phosphorylation of transcription factors. *Curr Opin Cell Biol* 6: 415-424
14. Honma Y, Kasukabe T, Hozumi M (1978) Induction of lysozyme activity by adenosine 3':5'-cyclic monophosphate in cultured mouse myeloid leukemia cells. *Biochem Biophys Res Commun* 82: 1246-1250
15. Shayo C, Davio C, Brodsky A, Mladovan, A G, Legnazzi, BL, et al. (1997) Histamine modulates the expression of c-fos through cyclic AMP production via the H2 receptor in the human promonocytic cell line U937. *Mol. Pharmacol* 51: 983-990
16. Copsel S, Garcia C, Diez F, Vermeulen M, Baldi A, et al. (2011) Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and J Biol Chem 286:6979-88
17. Ohta A (2016) A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment. *Front Immunol* 7:109
18. Mikhailov A, Sokolovskaya A, Yegutkin GG, Amdahl H, West A, et al. (2008) CD73 participates in cellular multiresistance program and protects against TRAIL-induced apoptosis. *J Immunol* 181:464-475
19. Serra S, Horenstein AL, Vaisitti T, Brusa D, Rossi D, et al. (2011) CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. *Blood* 118:6141-6152
20. Chiavegatti T, Costa VL Jr, Araújo MS, Godinho RO (2008) Skeletal muscle expresses the extracellular cyclic AMP-adenosine pathway. *Br J Pharmacol* 153: 1331-1340
21. Duarte T, Menezes-Rodrigues FS, Godinho RO (2012) Contribution of the extracellular cAMP-adenosine pathway to dual coupling of β_2 -adrenoceptors to Gs and Gi proteins in mouse skeletal muscle. *J Pharmacol Exp Ther* 341: 820-828
22. Caricati-Neto A, Garcia AG, Bergantin LB (2015) Pharmacological implications of the Ca²⁺/cAMP signaling interaction: from risk for antihypertensive therapy to potential for neurological and psychiatric disorders. *Pharmacol Res Perspect* 3(5): e00181.
23. Bergantin LB, Caricati-Neto A (2016) Challenges for the pharmacological treatment of neurological and psychiatric disorders: Implications of the Ca²⁺/cAMP intracellular signalling interaction. *Eur J Pharmacol* 788: 255-260
24. Bergantin LB, Caricati-Neto A (2016) Novel Insights for of Parkinson's disease: Pharmacological Modulation of the Ca²⁺/cAMP Signalling Interaction. *Austin Neurol Neurosci* 1: 1009
25. Bergantin LB, Caricati-Neto A (2016) Recent advances in pharmacotherapy of neurological and psychiatric disorders promoted by discovery of the role of Ca²⁺/cAMP signaling interaction in the neurotransmission and neuroprotection. *Adv Pharmacol J* 1: 66-70
26. Errante PR, Caricati-Neto A, Bergantin LB (2017) Insights for the inhibition of cancer progression: Revisiting Ca²⁺ and cAMP signalling pathways. *Adv Cancer Prev* 2: e103